<DOC>
	<DOC>NCT00849290</DOC>
	<brief_summary>This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)</brief_summary>
	<brief_title>Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Objective disease progression Subjects must have been enrolled in the APCPlacebo arm of D9902B (NCT00065442) Infection requiring IV antibiotics Treatment with anticancer interventions within 14 days prior to enrollment Any medical condition which could compromise the study's objectives (discretion from sponsor)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>